{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Johnson M"],"funding":["Pfizer","NCI NIH HHS"],"pagination":["2517-2526"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9359741"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["28(12)"],"pubmed_abstract":["<h4>Purpose</h4>ARRY-382 (PF-07265804) is a selective inhibitor of colony-stimulating factor-1 receptor. We evaluated the safety and preliminary efficacy of ARRY-382 plus pembrolizumab in patients with advanced solid tumors.<h4>Patients and methods</h4>This was an open-label, multicenter, Phase 1b/2 study (NCT02880371) performed over September 1, 2016 to October 24, 2019. In the Phase 1b dose-escalation, patients with selected advanced solid tumors received ARRY-382 [starting dose 200 mg once daily (QD) orally] plus pembrolizumab [2 mg/kg intravenously (IV) every 3 weeks (Q3W)]. Phase 2 patients had: Pancreatic ductal adenocarcinoma (PDA); programmed cell death protein-1 (PD-1)/PD-ligand 1 (PD-L1) inhibitor-refractory (PD-1/PD-L1 IR) advanced solid tumors; or platinum-resistant ovarian can"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study."],"pmcid":["PMC9359741"],"funding_grant_id":["P30 CA054174","P30CA054174"],"pubmed_authors":["Rothenberg SM","Kunk PR","Lewis K","Sarantopoulos J","Lee P","Johnson M","Golden A","Sukari A","Dudek AZ","Goldman JW","Call J","Zhang Y","Gainor JF","Harney A"],"additional_accession":[]},"is_claimable":false,"name":"ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study.","description":"<h4>Purpose</h4>ARRY-382 (PF-07265804) is a selective inhibitor of colony-stimulating factor-1 receptor. We evaluated the safety and preliminary efficacy of ARRY-382 plus pembrolizumab in patients with advanced solid tumors.<h4>Patients and methods</h4>This was an open-label, multicenter, Phase 1b/2 study (NCT02880371) performed over September 1, 2016 to October 24, 2019. In the Phase 1b dose-escalation, patients with selected advanced solid tumors received ARRY-382 [starting dose 200 mg once daily (QD) orally] plus pembrolizumab [2 mg/kg intravenously (IV) every 3 weeks (Q3W)]. Phase 2 patients had: Pancreatic ductal adenocarcinoma (PDA); programmed cell death protein-1 (PD-1)/PD-ligand 1 (PD-L1) inhibitor-refractory (PD-1/PD-L1 IR) advanced solid tumors; or platinum-resistant ovarian can","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jun","modification":"2026-05-28T03:42:02.705Z","creation":"2025-04-04T20:21:53.91Z"},"accession":"S-EPMC9359741","cross_references":{"pubmed":["35302585"],"doi":["10.1158/1078-0432.CCR-21-3009"]}}